{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:21:11Z","timestamp":1769595671469,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/SAU-ONC\/116164\/2009"],"award-info":[{"award-number":["PTDC\/SAU-ONC\/116164\/2009"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/CVT\/115703\/2009"],"award-info":[{"award-number":["PTDC\/CVT\/115703\/2009"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3171-2","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T03:00:06Z","timestamp":1489460406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo"],"prefix":"10.1186","volume":"17","author":[{"given":"Alexandre","family":"Trindade","sequence":"first","affiliation":[]},{"given":"Dusan","family":"Djokovic","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Gigante","sequence":"additional","affiliation":[]},{"given":"Liliana","family":"Mendon\u00e7a","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-3635","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Duarte","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"issue":"4 Suppl 3","key":"3171_CR1","first-page":"7","volume":"19","author":"RK Jain","year":"2005","unstructured":"Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19(4 Suppl 3):7\u201316.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"3171_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24\u201340.","journal-title":"Nat Clin Pract Oncol"},{"issue":"29","key":"3171_CR3","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25(29):4557\u201361.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3171_CR4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nbt1323","volume":"25","author":"F Shojaei","year":"2007","unstructured":"Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber H-P, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b\u2009+\u2009Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8):911\u201320.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3171_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"JML Ebos","year":"2011","unstructured":"Ebos JML, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"3171_CR6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1757-2215-7-57","volume":"7","author":"G Aravantinos","year":"2014","unstructured":"Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res. 2014;7:57.","journal-title":"J Ovarian Res"},{"key":"3171_CR7","first-page":"594930","volume":"2014","author":"YX Chen","year":"2014","unstructured":"Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, Xie DR. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract. 2014;2014:594930.","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"3171_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M P\u00e0ez-Ribes","year":"2009","unstructured":"P\u00e0ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi\u00f1als F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220\u201331.","journal-title":"Cancer Cell"},{"issue":"20","key":"3171_CR9","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1101\/gad.1239004","volume":"18","author":"A Duarte","year":"2004","unstructured":"Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 2004;18(20):2474\u20138.","journal-title":"Genes Dev"},{"issue":"45","key":"3171_CR10","doi-asserted-by":"crossref","first-page":"15949","DOI":"10.1073\/pnas.0407290101","volume":"101","author":"NW Gale","year":"2004","unstructured":"Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A. 2004;101(45):15949\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"3171_CR11","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1101\/gad.1239204","volume":"18","author":"LT Krebs","year":"2004","unstructured":"Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev. 2004;18(20):2469\u201373.","journal-title":"Genes Dev"},{"issue":"9","key":"3171_CR12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm2009","volume":"7","author":"SJ Bray","year":"2006","unstructured":"Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678\u201389.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"3171_CR13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.devcel.2009.01.015","volume":"16","author":"L-K Phng","year":"2009","unstructured":"Phng L-K, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196\u2013208.","journal-title":"Dev Cell"},{"issue":"2-3","key":"3171_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1432-0436.2001.690207.x","volume":"69","author":"C Mailhos","year":"2001","unstructured":"Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 2001;69(2-3):135\u201344.","journal-title":"Differentiation"},{"issue":"1","key":"3171_CR15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/1471-2407-10-641","volume":"10","author":"D Djokovic","year":"2010","unstructured":"Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, et al. Combination of Dll4\/Notch and Ephrin-B2\/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 2010;10(1):641.","journal-title":"BMC Cancer"},{"issue":"11","key":"3171_CR16","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2006-12-063933","volume":"109","author":"JS Scehnet","year":"2007","unstructured":"Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007;109(11):4753\u201360.","journal-title":"Blood"},{"issue":"7122","key":"3171_CR17","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nature05355","volume":"444","author":"I Noguera-Troise","year":"2006","unstructured":"Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032\u20137.","journal-title":"Nature"},{"issue":"17","key":"3171_CR18","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1158\/0008-5472.CAN-05-4226","volume":"66","author":"P Hainaud","year":"2006","unstructured":"Hainaud P, Contrer\u00e8s J-O, Villemain A, Liu L-X, Plou\u00ebt J, Tobelem G, Dupuy E. The role of the vascular endothelial growth factor-delta-like 4 Ligand\/Notch4-Ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res. 2006;66(17):8501\u201310.","journal-title":"Cancer Res"},{"issue":"16","key":"3171_CR19","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-06-0285","volume":"12","author":"NS Patel","year":"2006","unstructured":"Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL, Harris AL. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res. 2006;12(16):4836\u201344.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3171_CR20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.bjc.6605368","volume":"101","author":"AM Jubb","year":"2009","unstructured":"Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li J-L, Leek R, Tan EY, Singh B, Mortensen NJ, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009;101(10):1749\u201357.","journal-title":"Br J Cancer"},{"issue":"4","key":"3171_CR21","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2353\/ajpath.2010.090908","volume":"176","author":"AM Jubb","year":"2010","unstructured":"Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li J-L, Allen P, Leek R, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 2010;176(4):2019\u201328.","journal-title":"Am J Pathol"},{"issue":"5","key":"3171_CR22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2559.2009.03279.x","volume":"54","author":"JC Martinez","year":"2009","unstructured":"Martinez JC, M\u00fcller MM, Turley H, Steers G, Choteau L, Li J-L, Sainson R, Harris AL, Pezzella F, Gatter KC. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 2009;54(5):598\u2013606.","journal-title":"Histopathology"},{"issue":"2","key":"3171_CR23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.stem.2009.05.019","volume":"5","author":"T Hoey","year":"2009","unstructured":"Hoey T, Yen W-C, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park I-K, Sato A, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5(2):168\u201377.","journal-title":"Cell Stem Cell"},{"key":"3171_CR24","doi-asserted-by":"crossref","unstructured":"Fischer M, Yen W-C, Kapoun AM, Wang M, O\u2019Young G, Lewicki J, Gurney A, Hoey T. Anti-DLL4 inhibits growth and reduces tumor initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2010.","DOI":"10.1158\/0008-5472.CAN-10-2817"},{"issue":"7122","key":"3171_CR25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nature05313","volume":"444","author":"J Ridgway","year":"2006","unstructured":"Ridgway J, Zhang G, Wu Y, Stawicki S, Liang W-C, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083\u20137.","journal-title":"Nature"},{"issue":"23","key":"3171_CR26","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1158\/0008-5472.CAN-07-0969","volume":"67","author":"J-L Li","year":"2007","unstructured":"Li J-L, Sainson RCA, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67(23):11244\u201353.","journal-title":"Cancer Res"},{"key":"3171_CR27","doi-asserted-by":"crossref","unstructured":"Haller BK, Br\u00e5ve A, Wallgard E, Roswall P, Sunkari VG, Mattson U, Halleng\u00e4rd D, Catrina S-B, Hellstr\u00f6m M, Pietras K. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene. 2010.","DOI":"10.1038\/onc.2010.176"},{"issue":"4","key":"3171_CR28","doi-asserted-by":"crossref","first-page":"e18709","DOI":"10.1371\/journal.pone.0018709","volume":"6","author":"M Kal\u00e9n","year":"2011","unstructured":"Kal\u00e9n M, Heikura T, Karvinen H, Nitzsche A, Weber H, Esser N, Yl\u00e4-Herttuala S, Hellstr\u00f6m M. Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. PLoS One. 2011;6(4):e18709.","journal-title":"PLoS One"},{"issue":"7239","key":"3171_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/458686b","volume":"458","author":"EC Hayden","year":"2009","unstructured":"Hayden EC. Cutting off cancer\u2019s supply lines. Nature. 2009;458(7239):686\u20137.","journal-title":"Nature"},{"issue":"7","key":"3171_CR30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2217\/fon.10.62","volume":"6","author":"JL Li","year":"2010","unstructured":"Li JL, Jubb AM, Harris AL. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 2010;6(7):1099\u2013103.","journal-title":"Future Oncol"},{"issue":"7282","key":"3171_CR31","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1038\/nature08751","volume":"463","author":"M Yan","year":"2010","unstructured":"Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7282):E6\u20137.","journal-title":"Nature"},{"issue":"9","key":"3171_CR32","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1073\/pnas.0611177104","volume":"104","author":"S Suchting","year":"2007","unstructured":"Suchting S, Freitas C, le Noble F, Benedito R, Br\u00e9ant C, Duarte A, Eichmann A. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007;104(9):3225\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5422","key":"3171_CR33","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","volume":"284","author":"J Holash","year":"1999","unstructured":"Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994\u20138.","journal-title":"Science"},{"issue":"5","key":"3171_CR34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2007-11-126045","volume":"112","author":"M Segarra","year":"2008","unstructured":"Segarra M, Williams CK, de la Luz SM, Bernardo M, McCormick PJ, Maric D, Regino C, Choyke P, Tosato G. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood. 2008;112(5):1904\u201311.","journal-title":"Blood"},{"issue":"28","key":"3171_CR35","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.3748\/wjg.v19.i28.4486","volume":"19","author":"GG Li","year":"2013","unstructured":"Li GG, Li L, Li C, Ye LY, Li XW, Liu DR, Bao Q, Zheng YX, Xiang DP, Chen L, et al. Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells. World J Gastroenterol. 2013;19(28):4486\u201394.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3171_CR36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2007-09-112748","volume":"112","author":"A Trindade","year":"2008","unstructured":"Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS, Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008;112(5):1720\u20139.","journal-title":"Blood"},{"issue":"3","key":"3171_CR37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0022-3565(24)36522-X","volume":"280","author":"LD Mayer","year":"1997","unstructured":"Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther. 1997;280(3):1406\u201314.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3171_CR38","doi-asserted-by":"crossref","first-page":"e29863","DOI":"10.1371\/journal.pone.0029863","volume":"7","author":"A Trindade","year":"2012","unstructured":"Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes AC, Lopes-da-Costa L, Krasnoperov V, Liu R, Gill PS, et al. Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One. 2012;7(1):e29863.","journal-title":"PLoS One"},{"key":"3171_CR39","doi-asserted-by":"crossref","unstructured":"Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin\/simian virus 40 oncogenes. Nature. 1985;315(6015):115\u201322.","DOI":"10.1038\/315115a0"},{"key":"3171_CR40","doi-asserted-by":"crossref","unstructured":"Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284(5415):808\u201312.","DOI":"10.1126\/science.284.5415.808"},{"issue":"7204","key":"3171_CR41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature07083","volume":"454","author":"T Tammela","year":"2008","unstructured":"Tammela T, Zarkada G, Wallgard E, Murtom\u00e4ki A, Suchting S, Wirzenius M, Waltari M, Hellstr\u00f6m M, Schomber T, Peltonen R, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454(7204):656\u201360.","journal-title":"Nature"},{"issue":"6","key":"3171_CR42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrm2183","volume":"8","author":"RH Adams","year":"2007","unstructured":"Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"3171_CR43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/01.RES.81.4.567","volume":"81","author":"AL Wong","year":"1997","unstructured":"Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res. 1997;81(4):567\u201374.","journal-title":"Circ Res"},{"issue":"3","key":"3171_CR44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.83.3.233","volume":"83","author":"T Asahara","year":"1998","unstructured":"Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83(3):233\u201340.","journal-title":"Circ Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3171-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:50:24Z","timestamp":1750103424000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3171-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3171-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]},"article-number":"189"}}